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Aims Obesity and hyperlipidaemia are associated with insulin resistance (IR); however, the mechanisms responsible remain
incompletely understood. Pro-atherogenic hyperlipidaemic states are characterized by inﬂammation, oxidant stress,
and pathophysiologic oxidized lipids, including ligands for the scavenger receptor CD36. Here we tested the hypoth-
esis that the absence of CD36 protects mice from IR associated with diet-induced obesity and hyperlipidaemia.
Methods
and results
Adipose tissue from CD36
2/2 mice demonstrated a less inﬂammatory phenotype and improved insulin signalling in
vivo and at the level of the adipocyte and macrophage. The pathophysiologic ligand oxidized low-density lipoprotein
(oxLDL) activated c-Jun N-terminal kinase (JNK) and disrupted insulin signalling in both adipocytes and macrophages
in a CD36-dependent manner. Macrophages isolated from CD36
2/2 mice after high-fat diet feeding elicited less JNK
activation and inhibition of insulin signalling in adipocytes after co-culture compared with wild-type macrophages.
Conclusion These data suggest that a CD36-dependent inﬂammatory paracrine loop between adipocytes and macrophages facili-
tates chronic inﬂammation and contributes to IR common in obesity and dyslipidaemia.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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1. Introduction
Because of its role in fatty acid transport and expression on insulin-
sensitive tissues, contribution of the class B scavenger receptor
CD36 to insulin resistance (IR) has been the focus of study. A
limited number of human studies have shown associations of CD36
with impaired insulin sensitivity.
1–3 In rodent models, CD36 inter-
action with fatty acids may play a role in the pathogenesis of metabolic
disorders such as IR, obesity, and non-alcoholic hepatic steatosis, and
absence of CD36-mediated lipid uptake in muscle or liver is capable of
preventing diet-induced lipotoxicity.
4–6 CD36 recognizes a variety of
ligands generated in settings of IR which may similarly contribute to
pathogenesis. For example, pro-atherogenic hyperlipidaemic states
are characterized by the generation of pathophysiologically oxidized
lipids which are highly associated with IR.
7,8 We showed that phos-
pholipids truncated in the sn-2 position present in oxidatively modi-
ﬁed low-density lipoprotein (oxLDL) provide the recognition site
for CD36 and subsequent signalling events, and uptake results in
macrophage foam cell formation in vitro and in vivo,
9,10 and provide a
mechanistic link between oxidant stress, platelet hypersensitivity,
and thrombosis.
11 In this way, we hypothesize that oxidized lipids
may link hyperlipidaemia, obesity, and IR.
Because inﬂammation and oxidant stress associated with obesity
are particularly manifest at the level of adipose tissue
12 where
CD36 is highly expressed, we tested whether pathological ligands
for CD36 disrupt insulin signalling in adipocytes through activation
of CD36-dependent signalling pathways. We hypothesized that
pro-atherogenic hyperlipidaemic states would potentiate a
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and their associated macrophages, facilitating the development of
chronic inﬂammation in adipose tissue that underlies the insulin-
resistant state common to obesity and cardiovascular disease. We
describe here that absence of CD36 protects mice from IR associated
with diet-induced obesity and hyperlipidaemia, and that in adipocytes
and macrophages, oxLDL activates c-Jun N-terminal kinase (JNK) and
disrupts insulin signalling in a CD36-dependent manner.
2. Methods
2.1 Animals and diets
Littermate-derived wild-type (WT) and CD36
2/2 (10× backcrossed
to C57Bl/6), apoE
2/2 and apoE
2/2/CD36
2/2 (7× backcrossed to
C57Bl/6), and LDLR
2/2 and LDLR
2/2/CD36
2/2 mice (8× back-
crossed to C57Bl/6) were as previously described
10,13 except
further backcrossed as indicated. Lyn
2/2 (6× backcrossed to
C57Bl/6) and Fyn
2/2 (1× backcrossed to C57Bl/6) mice were from
the Jackson Laboratory. MyD88
2/2 mice (7× backcrossed to
C57Bl/6) were a generous gift from Clifford Harding (Case
Western Reserve University). Age- and sex-matched mice were fed
a high-fat diet (HFD) (36%, w/w, adjusted calories from fat,
Bio-Serv S3282) for 8–12 weeks or in the case of LDLR
2/2 strains,
a high-fat/high-cholesterol diet (Harlan Teklad 96121); controls
were maintained on chow (Harlan Teklad, TD 2918). All animal pro-
cedures were priorly approved by the Institutional Animal Care and
Use Committee, carried out in an AAALAC accredited facility, and
the investigation conforms with the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996).
2.2 In vitro metabolic analyses
Tail vein blood for plasma was collected 1 week prior to sacriﬁce after
overnight fast in 5 mM EDTA-dipotassium salt. Non-esteriﬁed fatty
acids and triacylglycerol were assayed using kits from Wako, and fasting
insulin was measured with the Ultrasensitive Mouse Insulin ELISA
(ALPCO). Plasma lipoprotein proﬁles were determined by fast protein
liquid chromatography of 10 mL aliquots on two Superose 6 columns
with continuous online detection of cholesterol in the eluant.
14
For glucose tolerance testing (GTT), mice were fasted overnight
and injected (intraperitoneal) with 2 mg glucose/g of body weight.
Tail vein blood glucose was measured using a One Touch Basic gluc-
ometer (Johnson & Johnson). For insulin tolerance tests, mice were
challenged with an intraperitoneal injection of human insulin
(0.75 mU/g, Novulin-R) after a 4 h fast. For biochemical analysis of
insulin signalling, human insulin (5 mU/g) was injected intravenously
after a 4 h fast. After 5 min, gonadal WAT, quadriceps, and liver
were isolated and snap-frozen in liquid nitrogen.
2.3 Reagents and cell culture
Tissue culture media, supplements, and reagents were as described in
detail in Supplementary material online, Methods. 3T3L1 and stromal
vascular fraction (SVF) pre-adipocytes were differentiated and cul-
tured using the Adipogenesis Kit (Cayman Chemical). Isolation and
culture of resident peritoneal macrophages (RPM) and SVF pre-
adipocytes are described in Supplementary material online,
Methods. For all in vitro experiments examining insulin signalling,
cells were treated with 100 nM insulin for the ﬁnal 20 min prior to
harvest.
2.4 Detection of reactive oxygen species,
cytokine/chemokines, and related assays
Oxidative burst in pooled RPM and SVF macrophages was measured
using Fc OxyBURST Green assay (Molecular Probes; described in
detail in Supplementary material online, Methods). Plasma cytokine
levels were determined by a multiplex ELISA cytokine array (Q-Plex
Mouse Cytokine Array-Screen IR 16-plex; Quansys Biosciences) and
plasma interferon (IFN-g) was conﬁrmed by ELISA (Bender Medsys-
tems). Cytokine levels in conditioned media (CM) pooled from
RPM and 3T3L1 adipocytes were determined using the Proteome
Proﬁler Mouse Cytokine Array, Panel A (R&D Systems). Arginase
activity was assayed using the QuantiChromTM Arginase Assay (BioAs-
say Systems); free glycerol was assayed using the Free Glycerol
Reagent (Sigma).
2.5 Glucose uptake
Glucose uptake into 3T3L1 adipocytes was measured using 2-NBDG
(Molecular Probes), a ﬂuorescent derivative of glucose as previously
described
15,16 and described in detail in Supplementary material
online, Methods.
2.6 In vitro migration assay
Migration of RPM was measured in a modiﬁed Boyden chamber
migration assay using Transwell inserts with an 8 mM porous membrane
(Corning). Cells were loaded into the migration chamber with CM from
WT or CD36
2/2 adipocytes treated for 12 h + oxLDL. After allowing
cell migration for 16 h, cells were removed from the upper side of the
membranes, and nuclei of migratory cells on the lower side of
the membrane were stained with 4′,6-diamidino-2-phenylindole. The
nuclei were visualized by ﬂuorescence microscopy, and the average
number of migratory cells was determined from averaging four ﬁelds.
2.7 Preparation of tissue homogenates, cell
lysate, and immunoblotting
Equal amounts of protein were prepared using standard biochemical
methods (described in detail in Supplementary material online,
Methods) and subjected to sodium dodecyl sulfate–polyacrylamide
gel electrophoresis and electrotransfer to Immobilon-P membranes
(Millipore). Membranes were incubated with the following antibodies:
phospho-SAPK/JNK (Thr
183Tyr
185), phospho-c-Jun (Ser
63), SAPK/
JNK, phospho-IRS-1 (Ser
307), IRS-1, phospho-AKT (Ser
473), AKT,
and IkBa (Cell Signaling Technology); Fyn, Lyn, and actin (Santa
Cruz Biotechnology); phospho-IRS-1 (Tyr
608) (Millipore); iNOS (BD
Bioscience); CD36 (Novus Biologicals). Detection was performed
with the SNAP i.d.TM Protein Detection System (Millipore) and
Super Signal Chemiluminescent Substrate Products (Pierce), and
band intensity was analyzed by densitometry (ImageJ v1.37).
2.8 Histology and immunohistochemistry
Immunohistochemistry was performed on deparaﬁnized 5 mm serial
sections incubated in 3% hydrogen peroxide followed by 5% milk,
and then overnight (48C) with anti-MAC-2 (1:500; Cedarlane) or
isotype control. Histochemical reactions were performed using the
EnVision
w Doublestain System (DakoCytomation) and counter-
stained with haematoxylin.
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Data presented are mean+standard error of the mean. Data
obtained were ﬁrst tested for normality using the D’Agostino–
Pearson omnibus test. If the data did not pass the normality test,
the Tukey test (for multiple groups) or the Mann–Whitney rank
sum test was used to compare the data. If the data did pass the nor-
mality test, parametric comparisons were performed. If more than
two groups were compared, one-way analysis of variance was per-
formed prior to comparison of individual groups with the unpaired
Student’s t–test with Bonferroni’s correction for multiple compari-
sons. If only two groups of normal data were compared, the Student’s
t-test was used without correction. Statistical analysis was performed
using GraphPad Prism
w.
3. Results
3.1 CD36 contributes to impaired glucose
tolerance and obesity
We measured parameters of glucose and lipid metabolism in age-
matched male and female mice fed the HFD for 8 weeks. Before
diet treatment, all cleared a bolus of glucose within 2 h (not
shown). After, GTT was greatly impaired in WT vs. CD36
2/2 mice
(Figure 1A); area under the curve (AUC) was signiﬁcantly greater in
WT males (37%) and females (33%). Fasting hyperinsulinaemia was
signiﬁcantly less (P , 0.01) in CD36
2/2 animals (Supplementary
material online, Figure S1), as was fasting plasma free glycerol, a
measure of lipolysis (14% lower, P , 0.05) (Supplementary material
Figure 1 Protection from diet-induced IR in CD36
2/2 mice. Intraperitoneal GTT for mice of the indicated sex and genotype fed the HFD for 8
weeks (A, C) or male mice at 4 weeks (B). GTT AUC analysis is shown on right. n ≥ 5 per group.
D.J. Kennedy et al. 606online, Figure S2). Interestingly, WT and CD36
2/2 mice had equivalent
levels of free fatty acids and LDL, suggesting that metabolic improve-
ments in CD36
2/2 mice were not due to grossly detectable changes
in circulating ligands (Supplementary material online, Table S1).
Despite consuming similar amounts of food (Supplementary material
online, Figure S3), CD36
2/2 mice were protected from HFD-induced
weight gain (Supplementary material online, Figure S4) and adiposity
(36% lower, P , 0.05) (Supplementary material online, Figure S5).
CD36 has been shown to be a co-receptor for Toll-like receptors
(TLRs).
17–19 TLR signalling by a subset of ligands, including oxLDL and
fatty acids, is propagated by recruitment of the universal adaptor mol-
ecule MyD88.
20 MyD88
2/2 mice fed the HFD were not protected
from an insulin-resistant phenotype (Figure 1B; Supplementary
material online, Figure S6).
To control for degree of adiposity as a potential confounder, we
studied 12-week HFD-fed apolipoprotein E null (apoE
2/2) and
apoE
2/2/CD36
2/2 mice; these animals have equivalent body
weights and adiposity (Supplementary material online, Figure S7).
GTT showed greater impairment (29% greater AUC, P , 0.05) in
male and female apoE
2/2 mice (Figure 1C). There was a two-fold
increase in the level of fasting insulin in apoE
2/2 mice; levels in
apoE
2/2/CD36
2/2 animals were similar to NC-fed controls (Sup-
plementary material online, Figure S8). Using a second hyperlipidaemic
model, the LDL receptor null (LDLR
2/2), we observed pronounced
impairment of glucose tolerance in LDLR
2/2 vs. LDLR
2/2/CD36
2/2
mice fed a high-fat, high-cholesterol (1.25%) diet (Supplementary
material online, Figure S9).
3.2 CD36 contributes to impaired insulin
signalling in adipose tissue
To identify sites of IR, HFD-fed WT and CD36
2/2 mice were injected
with insulin, and tissues harvested for biochemical analysis. There was
decreased phosphorylation of insulin-stimulated Akt, indicating
impaired insulin signalling, in gonadal white adipose tissue (WAT;
Figure 2A), but not in the quadriceps (Supplementary material
online, Figure S10) or liver (Supplementary material online, Figure
S11) of WT vs. CD36
2/2 mice.
Metabolic stress from HFD feeding is also known to cause acti-
vation of the regulatory mitogen-activated protein (MAP) kinase
JNK and trigger the development of IR.
21 WAT from HFD-fed
CD36
2/2 mice had signiﬁcantly less JNK activation vs. WT (P ,
0.05) (Figure 2B) and a similar decrease was observed in HFD-fed
apoE
2/2/CD36
2/2 vs. apoE
2/2 mice (Supplementary material
online, Figure S12).
JNK can directly induce IR by serine phosphorylation of the adapter
protein, insulin receptor substrate 1 (IRS-1), at inhibitory sites which
in turn decreases IRS-1 tyrosine phosphorylation and blocks insulin
receptor signalling.
22 Adipose tissue from WT mice had three-fold
less (P , 0.05) IRS-1 tyrosine phosphorylation (pY
608) vs. CD36
2/2
mice (Figure 2C). Similar impairments in insulin signalling were
Figure 2 CD36 contributes to inﬂammation and macrophage inﬁltration in adipose tissue after HFD. In vivo insulin signalling assay of AKT phos-
phorylation in (A) WAT of 8-week HFD CD36
2/2 vs. WT mice. Representative immunoblots (left) and quantiﬁcation (right) of (B) JNK phosphoryl-
ation and (C) IRS-1 tyrosine phosphorylation from WAT of 8-week HFD mice. (D, F) MAC-2 staining of representative WAT sections from HFD mice,
and (E) quantiﬁcation of CLS (arrows) expressed as a percentage of CLS/100 adipocytes averaged from four separate ﬁelds. *P , 0.05; **P , 0.01 vs.
WT; n ≥ 5 per group.
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apoE
2/2/CD36
2/2 vs. apoE
2/2 mice (not shown).
3.3 CD36 contributes to inﬂammation and
macrophage inﬁltration in adipose tissue
Plasma from HFD-fed CD36
2/2 mice had lower levels of inﬂamma-
tory cytokines and chemokines vs. WT mice, including IFN-g
(27.2+1.0 vs. 35.6+3.4 pg/mL, P , 0.05), a Th1 cytokine involved
in fat inﬂammation. Inﬁltrating macrophages contribute to IR during
HFD-induced obesity
23 and monocyte chemotactic protein
(MCP)-1, a key chemokine involved in the recruitment of macro-
phages, was elevated in WT vs. CD36
2/2 plasma (4.4+1.1 vs.
2.2+0.2 pg/mL, P , 0.05). Histological examination of gonadal
WAT revealed four-fold fewer (P , 0.01) Mac-2 expressing ‘crown-
like structures’ (CLS; Figure 2D and E), hallmarks of adipose tissue
inﬂammation. WAT from HFD-fed apoE
2/2/CD36
2/2 mice had eight-
fold fewer (P , 0.01) CLS vs. apoE
2/2 WAT (Figure 2E and F).
3.4 CD36 contributes to an M1 phenotype
An important feature of adipose tissue inﬂammation and IR is the pre-
dominance of a classical M1 pro-inﬂammatory macrophage vs. an M2
anti-inﬂammatory tissue-residing macrophage.
23 M1 macrophages are
characterized by enhanced pro-inﬂammatory cytokine production as
well as a shift in the iNOS/arginase balance to iNOS, which favours
the generation of reactive oxygen species (ROS) such as NO. RPM
from HFD-fed WT mice showed two-fold or more increases in
several key inﬂammatory cytokines, including IFN-g, MCP-1,
MIP-1a, and TNF-a, vs. CD36
2/2 macrophages, under basal con-
ditions (Supplementary material online, Table S2) and in response to
oxLDL (Supplementary material online, Table S3). OxLDL-stimulated
WT RPM demonstrated signiﬁcantly greater ROS production
(Figure 3A), and macrophages isolated from the adipose SVF of
HFD-fed WT mice also had greater ROS production, both basally
and in response to oxLDL (Supplementary material online, Figure
S13). RPM from HFD-fed CD36
2/2 mice had nearly two-fold more
(P , 0.01) arginase activity vs. WT (Supplementary material online,
Figure S14). Additionally, CD36
2/2 macrophages expressed signiﬁ-
cantly less iNOS and NFkB (assessed indirectly as less IkBa degra-
dation) (Figure 3B). OxLDL treatment was associated with a 50%
increase in the expression of iNOS in WT macrophages, an effect
that was absent in CD36
2/2 macrophages (Supplementary material
online, Figure S15). In addition, WAT from HFD-fed CD36
2/2 mice
demonstrated 90% decreased iNOS expression (P , 0.01) and four-
fold greater arginase activity (P , 0.05) vs. WT WAT (Supplementary
material online, Figures S16 and 17).
Similar to our primary cell data, oxLDL treatment of the classic adi-
pocyte cell line, 3T3L1, resulted in at least two-fold increase in several
cytokines/chemokines important for macrophage recruitment, includ-
ing G-CSF, sICAM, IL-6, and MIP-2 (Supplementary material online,
Figure S18).
3.5 OxLDL promotes a CD36-dependent
IR phenotype in adipocytes
OxLDL increased JNK phosphorylation in 3T3L1 adipocytes and this
effect was inhibited by pre-incubation with a monoclonal antibody
(mAb) to CD36 (Supplementary material online, Figure S19). We
observed a 50% increase (P , 0.05) in p-cJun, a downstream target
of JNK, and this was attenuated by pre-treatment with either mAb
to CD36 or a pharmacologic inhibitor of JNK kinase (Figure 4A).
OxLDL treatment induced a two-fold increase (P , 0.05) in the
inhibitory serine phosphorylation (S
307) of IRS-1 and this effect was
also attenuated by mAb to CD36 and JNK kinase inhibition
(Figure 4B). Similarly, in primary adipocytes isolated from WT
gonadal WAT, oxLDL induced JNK activation, and this was completely
abrogated in CD36
2/2 cells (Figure 4C). We next differentiated adipo-
cytes from the SVF of gonadal WAT and observed that oxLDL treat-
ment induced a two-fold increase in p-cJun in WT but not CD36
2/2
adipocytes (Supplementary material online, Figure S20).
In addition to oxLDL, we also examined the effects of other CD36
ligands on insulin signalling in adipocytes, including advanced glycation
end products in bovine serum albumin (AGE-BSA), free fatty acids
(FA), and fatty acids exposed to the myeloperoxidase (MPO)/H2O2/
NO2-generating system (oxFA). Using adipocytes differentiated
from the SVF, we observed that both FA and oxFA treatment
induced  50% decrease in insulin-stimulated p-AKT levels in WT
and MyD88
2/2 adipocytes (P , 0.05) but had no effect on
CD36
2/2 adipocytes (Supplementary material online, Figure S21). It
is likely, however, that FA were already signiﬁcantly oxidized,
because precautions are not taken by the manufacturer to prevent
this. AGE-BSA did not induce signiﬁcant changes in JNK activation
or AKT phosphorylation (not shown).
CD36-dependent activation of MAP kinases has been previously
shown to be mediated by upstream activation of Src family kinases
in other cell types, and we explored whether this was the case in
Figure 3 CD36 contributes to a pro-inﬂammatory phenotype in macrophages after HFD. (A) Oxidative burst in RPM isolated from 8-week HFD
female mice treated with 50 mg/mL oxLDL over 60 min as described in Supplementary material online, Methods. (B) Representative immunoblots
(left) and quantiﬁcation (right) of iNOS and IkBa expression in RPM. *P , 0.05; **P , 0.01 vs. WT; n ≥ 5 per group.
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mycin A and Src kinases with PP2 were both capable of attenuating
JNK phosphorylation in 3T3L1 adipocytes (Supplementary material
online, Figure S22). Furthermore, oxLDL-induced inhibitory serine
phosphorylation of IRS-1 was also diminished by treatment with
PP2 (Supplementary material online, Figure S23).
We tested the involvement of Src family kinases previously shown to
have a role in oxLDL-CD36 responses (Fyn, Lyn) using adipocytes iso-
lated from knockout mice. Similar to CD36
2/2, the oxLDL-induced
increase in p-JNK was abrogated in adipocytes from Fyn
2/2 and
Lyn
2/2 mice (Figure 4C). Co-immunoprecipitation revealed that oxLDL
treatment of 3T3L1 adipocytes increased the association of CD36
w i t hF y na n dL y n( Figure 4D). These data suggest that either Fyn or
Lyn is sufﬁcient for JNK activation. In order to conﬁrm involvement in
vivo, GTT was performed on 4-week HFD-fed Lyn
2/2 mice. Lyn
2/2
mice exhibited improved glucose tolerance vs. WT (Figure 4E), but not
to the degree observed in CD36
2/2 mice. Given the redundancy in
Src kinases, however, it is not surprising that individual deletion of Lyn
does not produce a phenotype which completely mimics CD36 deletion.
3.6 oxLDL impairs adipocyte insulin
responses in a CD36-dependent manner
To understand the functional implications of oxLDL-mediated
changes in p-JNK, p-IRS-1, and p-AKT, we examined the effect of
oxLDL on physiologic correlates of insulin sensitivity in 3T3L1 adipo-
cytes. OxLDL treatment decreased glucose uptake by  15% (P ,
0.05), decreased adiponectin secretion by  45% (P , 0.01), and
increased adipocyte lipolysis (P , 0.05) (Supplementary material
online, Figures S24–S26). Each of these effects was attenuated by
pre-incubation with CD36 mAb.
3.7 HFD impairs macrophage insulin
signalling in a CD36-dependent manner
in vivo
We isolated RPM after HFD feeding to assess the effect of CD36
ligands in vivo. We observed increased phosphorylation of cJun and
decreased phosphorylation of AKT (Figure 5A and B) in RPM from
WT vs. CD36
2/2 mice.
3.8 CD36 contributes to impaired insulin
signalling in co-cultured adipocytes and
macrophages
Obesity is associated with inﬁltration of fat by macrophages, suggesting
they contribute to the inﬂammatory phenotype.
12,23 We co-cultured
3T3L1 adipocytes with RPM isolated from HFD-fed apoE
2/2 or
apoE
2/2/CD36
2/2 mice. Adipocytes co-cultured with direct contact
to apoE
2/2 macrophages showed increased p-cJun and decreased
Figure 4 OxLDL promotes CD36-dependent molecular and physiologic impairment of insulin signalling in adipocytes. Representative immunoblots
(left) and quantiﬁcation (right) of oxLDL-induced increases in phospho-c-Jun (A) and inhibitory phosphorylation of IRS-1 at serine 307 (B)i na
CD36-dependent manner in 3T3L1 adipocytes treated for 60 min with 50 mg/mL oxLDL and pre-incubated with a mAb to CD36 (5 mg/mL) or a
pharmacologic inhibitor of JNK kinase activity (SP600125, 20 mM). * P , 0.05 vs. control, quantiﬁcation summarized from at least three independent
experiments. (C) JNK phosphorylation in primary adipocytes isolated from mice and treated for 15 min with 50 mg/mL oxLDL. (D) 3T3L1 adipocytes
treated with 50 mg/mL oxLDL or control for 15 min were immunoprecipitated with a mAb to CD36 and then immunoblotted with polyclonal Abs to
Fyn, Lyn, or CD36. (E) GTT and AUC analysis (right) of 4-week HFD female mice of the indicated genotype; n ≥ 5 per group.
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608IRS-1) vs. those co-cultured
with apoE
2/2/CD36
2/2 macrophages (Figures 5C and D).
We next used an in vitro migration assay to assess the functional
interaction between macrophages and adipocytes exposed to CD36
ligands. WT and CD36
2/2 adipocytes were exposed to oxLDL or
control, washed extensively, and then incubated in serum-free
media. This CM was collected and placed in the bottom of a transwell
migration chamber. WT macrophages showed signiﬁcantly increased
migration when exposed to CM from WT adipocytes treated with
oxLDL compared with macrophages exposed to CM from
CD36
2/2 adipocytes treated with either oxLDL or control media
(P , 0.05, Figure 5E).
4. Discussion
In this report, we provide multiple lines of in vitro and in vivo evidence
supporting a mechanistic link between inﬂammation, oxidative stress,
hyperlipidaemia, and IR mediated by the type 2 scavenger receptor
CD36. This work supports the hypothesis that CD36 not only recog-
nizes pathological ligands and removes them, a physiologic role, but in
circumstances of obesity and hyperlipidaemia, these ligands also signal
via CD36 to affect inﬂammatory and insulin signalling pathways in a
pathophysiological response. This newly recognized role of CD36
has the potential to be targeted by therapeutics and thus provides a
relevant strategy to the clinically signiﬁcant problem of cardiovascular
morbidity and mortality associated with diabetes and IR. Our ﬁndings
suggest a novel role for CD36 in mediating a pro-inﬂammatory signal-
ling loop between macrophages and adipocytes that contributes to IR
in hyperlipidaemic settings.
CD36
2/2 mice in several backgrounds were protected from
chronic inﬂammation induced by HFD feeding: they demonstrated sig-
niﬁcantly lower levels of key circulating inﬂammatory cytokines, as
well as a decrease in CLS in adipose tissue. After HFD feeding, macro-
phages from CD36
2/2 mice secreted less pro-inﬂammatory cytokines
and ROS, had increased arginase activity, and decreased expression of
key inﬂammatory mediators. Indeed, CD36
2/2 macrophages them-
selves reﬂected attenuation of defects in the insulin signalling
pathway after HFD feeding. Direct co-culture of WT macrophages
from HFD-fed mice with 3T3L1 adipocytes gave rise to increased acti-
vation of JNK and impaired insulin signalling in adipocytes and this was
signiﬁcantly abrogated in adipocytes incubated with macrophages
lacking CD36. Further, CM from WT but not CD36
2/2 adipocytes
stimulated with oxLDL had important functional consequences for
macrophage migration: migration of macrophages was enhanced by
exposure to WT but not CD36
2/2 adipocyte CM, suggesting that
soluble factors released from adipocytes in response to CD36 signal-
ling may play an important role in macrophage recruitment and
inﬂammation in adipose tissue as observed in in vivo studies.
Figure 5 CD36 contributes to inﬂammation and impaired insulin signalling in macrophages with and without adipocyte co-culture. Representative
immunoblots (left) and quantiﬁcation (right) demonstrating CD36-dependent increased (A) phospho-c-Jun and decreased (B) phospho-AKT in RPM
cultured from 4-week HFD mice for 12 h. *P , 0.05; **P , 0.01 vs. WT; n ≥ 5 per group. Representative immunoblots (left) and quantiﬁcation (right)
for (C) phospho-cJun and (D) phospho-tyrosine-IRS-1 from 3T3L1 adipocytes co-cultured for 24 h with 0.5 × 10
6 RPM isolated from 8-week HFD
mice of the indicated genotypes. (E) Macrophage migration to CM from WT and CD36
2/2 adipocytes which had been previously exposed to oxLDL
or control media as described in Supplementary material online, Methods. *P , 0.05 vs. control.
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phage scavenger receptors are sometimes associated with an anti-
inﬂammatory phenotype because of their role in the clearance of
apoptotic cells and resolution of inﬂammation,
17,24,25 the data
herein indicate that CD36 is not necessarily a classic antiphylogistic
receptor. To be sure, our data do not exclude a role for CD36 in
M2 macrophages, where it has been shown to be upregulated by
PPARg and others have suggested may be involved in the increase
in fatty acid oxidation associated with the M2 phenotype.
26 Indeed,
TLR4 has also been shown to be highly expressed in M2 macrophages,
yet it plays a critical role in inﬂammation as well.
27
The contribution of CD36 to IR is controversial. Some genetic
cohort studies suggest that CD36 protects against IR,
28 whereas
other do not.
29 A quantitative trait locus in the region encoding the
CD36 gene has been linked to pathological components of the meta-
bolic syndrome.
1 Love-Gregory et al.
2 have demonstrated the associ-
ation of several single-nucleotide polymorphisms across this region—
including those that are documented to result in CD36 deﬁciency—
which conferred protection against the metabolic syndrome. Thus,
whether these CD36 polymorphisms represent a gain or loss of func-
tion or how they interact with other genetic determinants needs to
be established. The discrepancy between CD36 protecting from or pre-
disposing to IR may be accounted for by whether or not a
pro-inﬂammatory environment generates pathologic CD36 ligands,
and the tissues involved.
Diabetes and IR increase inﬂammation and ROS which may contrib-
ute to atherosclerosis by both creating modiﬁed LDL ligands and
causing endothelial dysfunction. The increase in pro-inﬂammatory
cytokines noted in our study and others
30 may not only increase
macrophage migration into adipose tissue, but also into the adventitia
of the vasculature. We have demonstrated that these proinﬂamma-
tory mediators may also cause signiﬁcant CD36-dependent cyto-
skeletal rearrangements which contribute to macrophage trapping.
31
The clinical sequelae of this dysfunction has important implications
for hypertension, myocardial infarction, and stroke. Thus, diabetes
and IR may contribute to a spectrum of cardiovascular diseases, and
therapeutics focused on CD36 signalling cascades provide an attrac-
tive target because of its established involvement in several of these
processes.
The data in this report support a pro-inﬂammatory role for CD36
in the setting of pro-atherogenic, hyperlipidaemic conditions and
agree with previous evidence from our lab and others.
13,30,32 This
ﬁnding is not surprising given the fact that CD36 recognizes ligands
that trigger an inﬂammatory innate immune response and that
others have shown that CD36 is a co-receptor for certain TLR
ligands including speciﬁc lipid and lipoprotein components of Gram-
positive bacteria cell walls, staphylococcal and mycobacterial organ-
isms, b-glucans on fungal pathogens, and erythrocytes infected with
falciparum malaria.
17,33,34 Ligand engagement of CD36 in these set-
tings can activate classic TLR signalling cascades resulting in NFkB acti-
vation and secretion of pro-inﬂammatory cytokines.
18,19
Some studies have suggested that adipose tissue macrophages are
both necessary and sufﬁcient for the development of IR in obesity.
Macrophage-speciﬁc deletion of JNK
35 or deletion of MCP-1 or its
receptor, CCR2
36,37 reverses HFD-induced IR. However, inﬂamma-
tory signals from the macrophage compartment alone may not be
mediators of diet-induced IR, as other reports have concluded that
only JNK inactivation in the parenchyma or adipose tissue is
capable of restoring insulin sensitivity after HFD feeding.
38,39 In any
case, work by others established that JNK plays an essential role in
the development of IR in obesity
21 where its activation leads to
phosphorylation of IRS-1 on serine 307. Increased p
S307IRS-1 uncou-
ples IRS-1 from the insulin receptor and decreases IRS-1 tyrosine
phosphorylation at sites necessary for interaction with PI-3K,
thereby impairing insulin action. We observed that in addition to
improvements in physiologic correlates of IR such as glucose toler-
ance and lipolysis, HFD-fed CD36
2/2 mice also had decreased
JNK activation and improved insulin signalling in adipose tissue.
Additionally, we demonstrated in vitro that oxLDL was able to acti-
vate JNK and increase inhibitory serine phosphorylation of IRS-1 in
adipocytes in a CD36-dependent manner. Further, we showed that
oxLDL-induced CD36-dependent changes in adipocytes associated
with important physiologic correlates of IR in vitro including impaired
glucose uptake, adiponectin secretion, and increased lipolysis. The
hypothesis that oxLDL participates in the development of IR is sup-
ported by the work of Scazzocchio et al.
8 in that they demonstrated
that oxLDL impaired both glucose uptake and the recruitment of
GLUT4 to plasma membranes in adipocytes and that these effects
were attenuated by pre-treatment with a mAb to CD36. Although
our studies have focused on oxLDL, the results do not exclude
effects of other CD36 ligands, because the HFD model generates
multiple insults. Although AGE-BSA did not appear to appreciably
disrupt insulin signalling, saturated fatty acids such as palmitate did
demonstrate CD36-dependent interference with insulin-stimulated
pAKT (Supplementary material online, Figure S21).
Work by our group and others has shown that modiﬁed lipopro-
teins, such as oxLDL, arise as byproducts during an inﬂammatory
response and play a key role in cardiovascular disease.
40,41 Podrez
et al.
9 characterized the structural basis of CD36 recognition sites
on oxLDL as modiﬁed phosphatidylcholine species, and more
recently, Greenberg et al.
42 have proposed the ‘lipid-whisker model’
to explain CD36 recognition of these truncated sn-2 fatty acids
present in phospholipids of various head group classiﬁcations. These
recognition sites are also found on apoptotic cells and effete rod
outer segments in the eye, and both must be cleared to prevent
disease, thus representing a homeostatic function of CD36.
25,43 The
pattern recognition function of CD36 has been conserved throughout
evolution across a diverse range of species.
44 This suggests a ‘molecu-
lar mimicry’ paradigm underlying our central hypothesis: although
evolution has selected for the ability of CD36 to be an effective lipo-
peptide sensor, inﬂammation associated with diet-induced obesity
now generates ligands equally capable of stimulating this receptor.
The results of the current study expand a purely ‘lipotoxic’ view of
HFD-induced IR suggested by others and now identiﬁes CD36 as a
central signalling molecule upstream of JNK activation in the cellular
pathway to IR induced by a HFD and CD36 ligands such as oxLDL.
In the current study, we used a variety of in vitro and in vivo
approaches, including pharmacologic inhibition, immunoprecipitation,
and genetic deletion of Src kinases to demonstrate that most probably
Fyn and Lyn associate with CD36 in adipocytes and act upstream of
JNK signalling. This is consistent with our previous observations of
CD36 signalling elsewhere.
45,46
Adipocytes express typical macrophage proteins including almost
their entire repertoire of cytokines and chemokines and in the
current study we noted signiﬁcant increases in several adipocyte cyto-
kines/chemokines elicited by oxLDL stimulation of importance for
macrophage recruitment. To further examine the contribution of
macrophage CD36 to HFD-induced IR, we analyzed data from a
CD36 and insulin resistance 611prior study from our group in which bone marrow (BM) transplan-
tation was used to determine the role of macrophage CD36 in ather-
osclerosis.
10 Male apoE
2/2 mice receiving apoE
2/2/CD36
2/2 BM had
a trend towards improved GTT after 12 weeks of HFD feeding (P ¼
0.054) when compared with those receiving apoE
2/2 BM. This data
coupled with the results of the current study suggest that in addition
to other compartments such as adipose tissue, macrophage CD36
may play an important role in IR associated with HFD feeding.
Our data provide evidence that absence of CD36 protects mice
from IR associated with diet-induced obesity and hyperlipidaemia
and that CD36 ligands such as oxLDL are capable of mediating a
CD36-dependent inﬂammatory paracrine loop between adipocytes
and their associated macrophages. This facilitates chronic inﬂam-
mation in adipose tissue and contributes to the IR common in
obesity and dyslipidaemia (Figure 6).
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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